Next-Generation Influenza Vaccines

Masaru Kanekiyo; Barney S Graham

doi:10.1101/cshperspect.a038448

Next-Generation Influenza Vaccines

Cold Spring Harb Perspect Med. 2021 Aug 2;11(8):a038448. doi: 10.1101/cshperspect.a038448.

Authors

Masaru Kanekiyo¹, Barney S Graham¹

Affiliation

¹ Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.

Abstract

Most currently used conventional influenza vaccines are based on 1940s technology. Advances in vaccine immunogen design and delivery emerging over the last decade promise new options for improving influenza vaccines. In addition, new technologies for immune profiling provide better-defined immune correlates of protection and precise surrogate biomarkers for vaccine evaluations. Major technological advances include single-cell analysis, high-throughput antibody discovery, next-generation sequencing of antibody gene transcripts, antibody ontogeny, structure-guided immunogen design, nanoparticle display, delivery and formulation options, and better adjuvants. In this review, we provide our prospective outlook for improved influenza vaccines in the foreseeable future.

Publication types

Research Support, N.I.H., Intramural
Review

MeSH terms

Adjuvants, Immunologic
Humans
Influenza Vaccines / immunology*
Influenza, Human / prevention & control*
Prospective Studies

Substances

Adjuvants, Immunologic
Influenza Vaccines